Adult T-cell leukemia: Future prophylaxis and immunotherapy

Mari Kannagi, Nanae Harashima, Kiyoshi Kurihara, Atae Utsunomiya, Ryuji Tanosaki, Masato Masuda

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

A small population of human T-cell leukemia virus Type I (HTLV-I) carriers develop adult T-cell leukemia after a long incubation period. The results of a series of experiments using animal models suggest that insufficiency of HTLV-I-specific T-cell response induced by vertical HTLV-I infection allows enlargement of the HTLV-I-infected cell reservoir in vivo, a crucial risk factor of adult T-cell leukemia. In this review it is proposed that prophylactic Tax-targeted vaccines for the high-risk group of adult T-cell leukemia, which is characterized by low HTLV-I-specific T-cell response and high proviral load, can reduce the risk. Immunological studies on adult T-cell leukemia patients after hematopoietic stem cell transplantation also suggest that Tax-targeted immunotherapy may be effective against full-blown disease, although its indication may be limited.

Original languageEnglish
Pages (from-to)369-376
Number of pages8
JournalExpert Review of Anticancer Therapy
Volume4
Issue number3
Publication statusPublished - 2004 Jun
Externally publishedYes

Fingerprint

Adult T Cell Leukemia Lymphoma
Human T-lymphotropic virus 1
Immunotherapy
T-Lymphocytes
Hematopoietic Stem Cell Transplantation
Vaccines
Animal Models
Infection
Population

Keywords

  • Adult T-cell leukemia
  • Hematopoietic stem cell transplantation
  • Human T-cell leukemia virus Type I
  • T-cell response
  • Tax

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Kannagi, M., Harashima, N., Kurihara, K., Utsunomiya, A., Tanosaki, R., & Masuda, M. (2004). Adult T-cell leukemia: Future prophylaxis and immunotherapy. Expert Review of Anticancer Therapy, 4(3), 369-376.

Adult T-cell leukemia : Future prophylaxis and immunotherapy. / Kannagi, Mari; Harashima, Nanae; Kurihara, Kiyoshi; Utsunomiya, Atae; Tanosaki, Ryuji; Masuda, Masato.

In: Expert Review of Anticancer Therapy, Vol. 4, No. 3, 06.2004, p. 369-376.

Research output: Contribution to journalReview article

Kannagi, M, Harashima, N, Kurihara, K, Utsunomiya, A, Tanosaki, R & Masuda, M 2004, 'Adult T-cell leukemia: Future prophylaxis and immunotherapy', Expert Review of Anticancer Therapy, vol. 4, no. 3, pp. 369-376.
Kannagi M, Harashima N, Kurihara K, Utsunomiya A, Tanosaki R, Masuda M. Adult T-cell leukemia: Future prophylaxis and immunotherapy. Expert Review of Anticancer Therapy. 2004 Jun;4(3):369-376.
Kannagi, Mari ; Harashima, Nanae ; Kurihara, Kiyoshi ; Utsunomiya, Atae ; Tanosaki, Ryuji ; Masuda, Masato. / Adult T-cell leukemia : Future prophylaxis and immunotherapy. In: Expert Review of Anticancer Therapy. 2004 ; Vol. 4, No. 3. pp. 369-376.
@article{e5961bf225bf4f99a2c9c5116e8d01b6,
title = "Adult T-cell leukemia: Future prophylaxis and immunotherapy",
abstract = "A small population of human T-cell leukemia virus Type I (HTLV-I) carriers develop adult T-cell leukemia after a long incubation period. The results of a series of experiments using animal models suggest that insufficiency of HTLV-I-specific T-cell response induced by vertical HTLV-I infection allows enlargement of the HTLV-I-infected cell reservoir in vivo, a crucial risk factor of adult T-cell leukemia. In this review it is proposed that prophylactic Tax-targeted vaccines for the high-risk group of adult T-cell leukemia, which is characterized by low HTLV-I-specific T-cell response and high proviral load, can reduce the risk. Immunological studies on adult T-cell leukemia patients after hematopoietic stem cell transplantation also suggest that Tax-targeted immunotherapy may be effective against full-blown disease, although its indication may be limited.",
keywords = "Adult T-cell leukemia, Hematopoietic stem cell transplantation, Human T-cell leukemia virus Type I, T-cell response, Tax",
author = "Mari Kannagi and Nanae Harashima and Kiyoshi Kurihara and Atae Utsunomiya and Ryuji Tanosaki and Masato Masuda",
year = "2004",
month = "6",
language = "English",
volume = "4",
pages = "369--376",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Adult T-cell leukemia

T2 - Future prophylaxis and immunotherapy

AU - Kannagi, Mari

AU - Harashima, Nanae

AU - Kurihara, Kiyoshi

AU - Utsunomiya, Atae

AU - Tanosaki, Ryuji

AU - Masuda, Masato

PY - 2004/6

Y1 - 2004/6

N2 - A small population of human T-cell leukemia virus Type I (HTLV-I) carriers develop adult T-cell leukemia after a long incubation period. The results of a series of experiments using animal models suggest that insufficiency of HTLV-I-specific T-cell response induced by vertical HTLV-I infection allows enlargement of the HTLV-I-infected cell reservoir in vivo, a crucial risk factor of adult T-cell leukemia. In this review it is proposed that prophylactic Tax-targeted vaccines for the high-risk group of adult T-cell leukemia, which is characterized by low HTLV-I-specific T-cell response and high proviral load, can reduce the risk. Immunological studies on adult T-cell leukemia patients after hematopoietic stem cell transplantation also suggest that Tax-targeted immunotherapy may be effective against full-blown disease, although its indication may be limited.

AB - A small population of human T-cell leukemia virus Type I (HTLV-I) carriers develop adult T-cell leukemia after a long incubation period. The results of a series of experiments using animal models suggest that insufficiency of HTLV-I-specific T-cell response induced by vertical HTLV-I infection allows enlargement of the HTLV-I-infected cell reservoir in vivo, a crucial risk factor of adult T-cell leukemia. In this review it is proposed that prophylactic Tax-targeted vaccines for the high-risk group of adult T-cell leukemia, which is characterized by low HTLV-I-specific T-cell response and high proviral load, can reduce the risk. Immunological studies on adult T-cell leukemia patients after hematopoietic stem cell transplantation also suggest that Tax-targeted immunotherapy may be effective against full-blown disease, although its indication may be limited.

KW - Adult T-cell leukemia

KW - Hematopoietic stem cell transplantation

KW - Human T-cell leukemia virus Type I

KW - T-cell response

KW - Tax

UR - http://www.scopus.com/inward/record.url?scp=2942542883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942542883&partnerID=8YFLogxK

M3 - Review article

C2 - 15161436

AN - SCOPUS:2942542883

VL - 4

SP - 369

EP - 376

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 3

ER -